Halozyme Therapeutics (HALO) Tops Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.45 +2.53%
EPS Growth %: +30.8%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +30.8%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $19.4 million.
Halozyme Therapeutics sees FY2015 revenue of $85-95 million, versus the consensus of $93.3 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
- Anthropic delays planned IPO from October to November - WSJ
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
